Abstract: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.
Type:
Application
Filed:
April 17, 2014
Publication date:
March 12, 2015
Applicant:
ACORDA THERAPEUTICS, INC.
Inventors:
Naweed MUHAMMAD, Gene Curtis JAMIESON, Keith R. BLEY, Sanjay CHANDA
Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
Type:
Grant
Filed:
March 7, 2013
Date of Patent:
March 3, 2015
Assignees:
Mayo Foundation for Medical Education & Research, Acorda Therapeutics, Inc.
Inventors:
Elliot A. Gruskin, Eric Chojnicki, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez
Abstract: An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution.
Abstract: The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
Abstract: This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.
Type:
Grant
Filed:
May 17, 2004
Date of Patent:
December 9, 2014
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Elliott A. Gruskin, Anthony O. Caggiano, Gargi Roy, Jennifer Iaci, Michael P. Zimber
Abstract: An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.
Abstract: Formulations and methods are provided for the treatment of pain, and neuropathic pain in particular. The formulations are eutectic mixtures of a capsaicinoid and a local anesthetic agent and/or an anti-pruritic agent.
Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.
Type:
Grant
Filed:
August 28, 2012
Date of Patent:
November 18, 2014
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Arturo J. Angel, Larry W. Litle, Keith R. Bley, Allan L. Wilcox, Gene Curtis Jamieson, Naweed Muhammad
Abstract: The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
Type:
Application
Filed:
February 24, 2014
Publication date:
October 30, 2014
Applicant:
ACORDA THERAPEUTICS, INC.
Inventors:
Elliott A. GRUSKIN, Rohini D'SOUZA, Gargi ROY, Anthony G. CAGGIANO
Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
Type:
Grant
Filed:
July 6, 2012
Date of Patent:
October 7, 2014
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Anthony O. Caggiano, Jennifer Iaci, Andrea Vecchione, Elizabeth Markensohn
Abstract: The present invention is directed to a method of improving functional recovery following a central nervous system contusion injury. The method includes administering a therapeutically effective amount of glycosaminoglycan degrading enzyme. The glycosaminoglycan degrading enzyme may be dermatan sulfate or chondroitin sulfate degrading enzymes. The central nervous system contusion injury may include a traumatic brain injury or a spinal cord injury. The functional recovery may include autonomic functions, sensory functions, motor functions or the like.
Type:
Application
Filed:
January 30, 2014
Publication date:
September 4, 2014
Applicant:
ACORDA THERAPEUTICS, INC.
Inventors:
Elliott A. GRUSKIN, Anthony O. CAGGIANO, Michael P. ZIMBER, Andrew R. BLIGHT
Abstract: The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.
Abstract: Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS.
Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
Type:
Grant
Filed:
April 20, 2012
Date of Patent:
July 22, 2014
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Elliott A. Gruskin, Jennifer F. Iaci, Andrea M. Vecchione, Sarah J. Kasperbauer, Gargi Roy
Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.
Type:
Application
Filed:
February 26, 2014
Publication date:
July 10, 2014
Applicant:
ACORDA THERAPEUTICS, INC.
Inventors:
Elliott A. GRUSKIN, Jack L. TSENG, Anthony O. CAGGIANO
Abstract: The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.
Abstract: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions are also provided.
Type:
Grant
Filed:
August 14, 2012
Date of Patent:
May 27, 2014
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Naweed Muhammad, Gene Curtis Jamieson, Keith R. Bley, Sanjay Chanda
Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.
Type:
Grant
Filed:
May 9, 2011
Date of Patent:
March 25, 2014
Assignee:
Acorda Therapeutics, Inc.
Inventors:
Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.